2009 Meeting of the European Association for the Study of Diabetes

EASD#

Title

Abstract

Poster

580

C-peptide Correction Method to Determine Exogenous Insulin Levels in Pharmacokinetic Studies Using Technosphere® Insulin

778

Inhaled GLP-1 and Exenatide: Different Effects on Pancreatic and Gastric Activity Following a Single Dose in Type 2 Diabetes Mellitus

779

Response to Inhaled GLP-1 is Dependent on Baseline Glucose

917

Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Plus Insulin Glargine QD vs Biaspart 70/30 Insulin BID in T2 DM Inadequately Controlled on Insulin With/Without Oral Agents

918

Reduced Incidence and Frequency of Hypoglycemia in an Integrated Analysis of Pooled Data from Clinical Trials of Subjects with Type 2 Diabetes Using Prandial Inhaled Technosphere® Insulin

919

Pulmonary Function Tests Remain Similar in Patients Who Received Technosphere® Insulin and in Patients Currently Receiving Standard Antidiabetic Therapy

920

Pulmonary Functions (Over 2 Years) in Diabetic Subjects Treated with Technosphere® Insulin or Usual Antidiabetic Treatment

921

Pulmonary Safety of Inhaled Technosphere® Insulin Therapy in Adults with Diabetes Using High-Resolution Computerized Tomography of the Chest

952

Technosphere® Insulin Suppresses Endogenous Glucose Production Earlier Than a Rapid-Acting Analog (Lispro) and an Inhaled Insulin (Exubera)

954

Pharmacokinetics of Technosphere® Insulin Unchanged in Patients with Chronic Obstructive Pulmonary Disease

955

Lung Deposition and Absorption of Insulin from Technosphere® Insulin

982

Comparative Efficacy and Safety of Technosphere® Insulin and a Rapid-Acting Analog Both Given With Glargine in Subjects with T1 DM in a 52-Week Study

983

Reduced Incidence and Frequency of Hypoglycemia in an Integrated Analysis of Pooled Data from Clinical Trials of Subjects with Type 1 Diabetes Using Prandial Inhaled Technosphere® Insulin

1009

Patient Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime Insulin Monomer Human (rDNA origin) Inhalation Powder (Technosphere® Insulin Inhalation Powder) or Metformin + Secretagogue or Both

215

Long-term Sustained Safety and Efficacy of Continued Use of Technosphere® Insulin in Subjects with Type 2 Diabetes (Oral Presentation)